Literature DB >> 29152084

The stromal morphological changes for differential diagnosis of uninodular high-grade dysplastic nodule and well-differentiated small hepatocellular carcinoma.

Long-Hai Feng1,2,3, Han Wang1,2,3, Hui Dong1,2,3, Yu-Yao Zhu1,2,3, Wen-Ming Cong1,2,3.   

Abstract

AIM: The stromal invasion has been regarded as the most valuable clue to distinguish high-grade dysplastic nodules (HGDNs) and well-differentiated small hepatocellular carcinomas (WD-SHCCs). The purposes of this study are to explore the stromal morphological changes for the differential diagnosis of these two equivocal lesions.
RESULTS: Based on the systemic studies of histological characteristics of HGDNs and WD-SHCCs, the stromal morphological changes, including sinusoid capillarization, ductular reaction and solitary artery, were performed to make a differential diagnosis between them. Separately, the solitary artery had the best sensitivity (93.75%) and accuracy (88.89%), and the sinusoid capillarization had the best specificity of 90.32%. On the whole, when at least 2 stromal morphological changes were abnormal, no matter what combination, the diagnostic performance was favorable and optimal with the highest accuracy of 92.06%, balancing the sensitivity (93.75%) and specificity (90.32%). The diagnostic performances were prior to the classical immunohistochemical panel comprising heat shock protein 70, glypican 3 and glutamine synthetase with the best sensitivity, specificity and accuracy of 62.50%, 80.65% and 71.43%, respectively.
MATERIALS AND METHODS: A retrospective case-control study was conducted on 63 patients who underwent partial hepatectomy for uninodular HGDNs or WD-SHCCs at the Eastern Hepatobiliary Surgery Hospital from 2005 to 2015.
CONCLUSIONS: The stromal morphological changes, containing sinusoid capillarization, ductular reaction and solitary artery could provide a more considerable diagnostic and differential diagnostic performance between HGDNs and WD-SHCCs. And they should be the key points during the histopathological diagnosis.

Entities:  

Keywords:  HGDNs; WD-SHCCs; diagnosis; differential diagnosis; stromal changes

Year:  2017        PMID: 29152084      PMCID: PMC5675636          DOI: 10.18632/oncotarget.20607

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  24 in total

1.  Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.

Authors:  Silvia Tremosini; Alejandro Forner; Loreto Boix; Ramon Vilana; Luis Bianchi; Maria Reig; Jordi Rimola; Carlos Rodríguez-Lope; Carmen Ayuso; Manel Solé; Jordi Bruix
Journal:  Gut       Date:  2012-01-27       Impact factor: 23.059

2.  [Diagnostic value of absent ductular reaction at hepatocellular-stromal boundaries in early stage hepatocellular carcinoma].

Authors:  Qin Zhang; Zhe Ma; Qi Xin; Gui-qiu Liu; Bing-bing Liu; Ying-tang Gao; Chuan-shan Zhang; Zhi Du
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2013-12

3.  Pathological diagnosis at early stage: reaching international consensus.

Authors:  Masamichi Kojiro
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

4.  Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver.

Authors:  Riccardo Inchingolo; Anna Maria De Gaetano; Davide Curione; Marzia Ciresa; Luca Miele; Maurizio Pompili; Fabio Maria Vecchio; Felice Giuliante; Lorenzo Bonomo
Journal:  Eur Radiol       Date:  2014-11-28       Impact factor: 5.315

5.  Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.

Authors:  Luca Di Tommaso; Giada Franchi; Young Nyun Park; Barbara Fiamengo; Annarita Destro; Emanuela Morenghi; Marco Montorsi; Guido Torzilli; Maurizio Tommasini; Luigi Terracciano; Luigi Tornillo; Raffaella Vecchione; Massimo Roncalli
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

6.  Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior.

Authors:  Xin-Yuan Lu; Tao Xi; Wan-Yee Lau; Hui Dong; Zhen Zhu; Feng Shen; Meng-Chao Wu; Wen-Ming Cong
Journal:  Ann Surg Oncol       Date:  2011-02-10       Impact factor: 5.344

Review 7.  Multistep human hepatocarcinogenesis: correlation of imaging with pathology.

Authors:  Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

8.  Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development.

Authors:  Mauro Borzio; Silvia Fargion; Franco Borzio; Anna Ludovica Fracanzani; Anna Maria Croce; Tommaso Stroffolini; Silvia Oldani; Rodolfo Cotichini; Massimo Roncalli
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

9.  Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications.

Authors:  Amedeo Sciarra; Luca Di Tommaso; Masayuki Nakano; Annarita Destro; Guido Torzilli; Matteo Donadon; Marco Maggioni; Silvano Bosari; Gaetano Bulfamante; Masanori Matsuda; Hideki Fujii; Tomoaki Ichikawa; Hiroyuki Morisaka; Katsuhiro Sano; Shintaro Ichikawa; Massimo Roncalli
Journal:  J Hepatol       Date:  2015-09-05       Impact factor: 25.083

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  2 in total

1.  Effects of knockout of lincRNA-p21 on the proliferation, migration and invasion ability of HepG2 liver cancer cells.

Authors:  Tongshan Wang; Jun Liu; Suihui Li; Zhengang Yuan; Xiangzhong Huang
Journal:  Oncol Lett       Date:  2019-04-01       Impact factor: 2.967

2.  Diagnosis of Liver Neoplasms by Computational and Statistical Image Analysis.

Authors:  Rong Xia; Amir M Boroujeni; Stephanie Shea; Yongsheng Pan; Raag Agrawal; Elhem Yousefi; M Isabel Fiel; M A Haseeb; Raavi Gupta
Journal:  Gastroenterology Res       Date:  2019-11-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.